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Background: Visceral pain is common symptom involved in many gastrointestinal disorders such as inflammatory
bowel disease. The underlying molecular mechanisms remain elusive. We investigated the molecular mechanisms
and the role for voltage gated calcium channel (VGCC) in the pathogenesis in a rat model of
2,4,6-trinitrobenzenesulfonic acid (TNBS) induced visceral inflammatory hypersensitivity.
Results: Using Agilent cDNA arrays, we found 172 genes changed significantly in dorsal root ganglia (DRG) of TNBS
treated rats. Among these changed genes, Cav1.2 and Cav2.3 were significantly up-regulated. Then the RT-PCR and
Western blot further confirmed the up-regulation of Cav1.2 and Cav2.3. The whole cell patch clamp recording of
acutely dissociated colonic specific DRG neurons showed that the peak IBa density was significantly increased in
colonic neurons of TNBS treated rats compared with control rats (−127.82 ± 20.82 pA/pF Vs −91.67 ± 19.02 pA/pF,
n = 9, *P < 0.05). To distinguish the different type of calcium currents with the corresponding selective channel
blockers, we found that L-type (−38.56 ± 3.97 pA/pF Vs −25.75 ± 3.35 pA/pF, n = 9, * P < 0.05) and R-type
(−13.31 ± 1.36 pA/pF Vs −8.60 ± 1.25 pA/pF, n = 9, * P < 0.05) calcium current density were significantly increased in
colonic DRG neurons of TNBS treated rats compared with control rats. In addition, pharmacological blockade with
L-type antagonist (nimodipine) and R-type antagonist (SNX-482) with intrathecal injection attenuates visceral pain in
TNBS induced inflammatory visceral hypersensitivity.
Conclusion: Cav1.2 and Cav2.3 in colonic primary sensory neurons play an important role in visceral inflammatory
hyperalgesia, which maybe the potential therapeutic targets.
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Abdominal pain and discomfort are amongst the most
vexing symptoms for patients suffering from inflammatory
bowel diseases such as Crohn’s ileitis and present a major
therapeutic challenge for physicians. The underline mecha-
nisms are still unknown. Therefore, it is essential to identify
the detailed molecular mechanisms that are involved
in inflammatory/infectious events leading to visceral
hypersensitivity both for understanding underlying mecha-
nisms and developing new therapies.
In the visceral sensory neurotransmission process,
the neurons that relay sensory information from the* Correspondence: yyz28@medmail.com.cn
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reproduction in any medium, provided the orintestine to the spinal cord are the dorsal root ganglia
(DRG) neurons. These pseudounipolar neurons have a
peripheral axon that travels to the intestine and a central
axon that project to sensory neurons in the dorsal horn
of the spinal cord. Taken together, current knowledge
suggests that changes in gene expression in DRGs may
contribute to the generation and development of inflam-
matory visceral hypersensitivity. Proposed mechanisms
that could account for the sensitization of primary sen-
sory afferents include increased expression of receptor
molecules involved in nociceptive pathways or alteration
of ionic channel properties. Here, we took a broader
approach, a cDNA array, to gain a comprehensive over-
view of the alteration of gene expression in DRGs after
TNBS induced visceral inflammation.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.molecularpain.com/content/9/1/15Voltage-gated calcium channels (VGCC) regulate rapid
and transient changes in intracellular calcium within excit-
able cells. Calcium entering the cell through these channels
serves as a second messenger, initiating intracellular events
such as contraction, secretion, protein phosphorylation,
gene expression, neurotransmitter release and action
potential firing patterns [1]. Within neurons of the DRG
the activity of calcium channels has been shown to play an
important role in nociceptive processing [2,3] and regula-
tion of calcium channel activity has been shown to modu-
late pain in clinical and experimental settings [2,4,5]. More
recently, agents which modulate the activity of the calcium
channel α2δ subunit have also been shown to exhibit
experimentally and clinically important pain relief [6].
However, a link between changes in voltage-gated calcium
channel of DRG and the occurrence of postinflammatory
hypersensitivity symptoms still has to be established.
The mechanism, for example, whether a specific sub-
type involves, or how or where they contribute to the
postinflammatory visceral pain, has remained to be
fully clarified, and the subtype channels could be viewed
as potential therapeutic targets for the treatment of
postinflammatory hypersensitivity symptoms.
Thus the aim of this study was to identify marked
changes in the expression of genes in DRG neurons
innervating the inflamed intestine. Then among these
diverse changed molecular, we are try to developing
successful therapies to target ion channels that promote
the sensitization of primary sensory afferents.
Results
Identification of differentially expressed genes
Using cDNA microarray, we found 172 genes changed
significantly in TNBS treated rats including ion channels,
receptors and signal transduction-related molecules
(Table 1). There were 13 channels strongly regulated
in DRG of TNBS-treated rats, including Ca2+ channels
(α1E and α1C), K+ channels, purinergic receptor P2X,
ryanodine receptor 1(Ryr1), glutamate receptor(AMPA2),
transient receptor potential cation channel(TRPC3) chan-
nels and so on (Table 1). The expression of Ca2+ channels
α1E and α1C subunit were the most strongly up-regulated
ion channels, ≈15-fold increase in the DRG 4 days after
TNBS treated. At the same time, 15 receptors were
founded to be strongly regulated in the DRG of TNBS-
treated rats (Table 1). Among these changed receptors, we
found that many receptors of inflammatory mediators such
as 5-hydroxytryptamine receptor (5-HTR, 1A and 2A),
prostaglandin E receptor (EP2), fibroblast growth factor
receptor (FGFR) and neuropeptide Y receptor were up-
regulated. In addition, a total of 22 signal transduction
modulators and effectors in the DRG were significantly
regulated (Table 1). Approximated 73% of these signal
transduction molecules were up-regulated, indicating thatthe activity of these signaling pathways may generally be
enhanced in the DRG after TNBS treated. Ras-related GTP
binding B was the most strongly up-regulated signal trans-
duction molecule, 12-fold increase as compared with the
control. In the same time, the RAS p21 protein activator
and RAS oncogene family (RAB39, RAB5A and RAB15)
were also significantly up-regulated 4 days after TNBS
treated. Mitogen-activated protein kinase 6 (ERK 3) and 8
(JNK 1) were also significantly up-regulated 4 days after
TNBS treated.
Real time PCR and Western blot analysis of Cav1.2 and
Cav2.3 expression levels
The samples were examined by RT-PCR in terms of the
above-mentioned steps to obtain cycle threshold (Ct)
values. Based on the Ct values, we calculated the targeted
gene expression level (ΔCt values). Table 2 shows that the
mRNA expression of Cav1.2 and Cav2.3 were significantly
increased in L6-S2 DRG of TNBS treated rats (n = 4 for
each group, * P < 0.05). We then compared Cav1.2 and
Cav2.3 protein expression levels with Western blot. We
found that the protein expression level of Cav1.2 and
Cav2.3 were also significantly increased in L6-S2 DRG of
TNBS treated group compared with control group (Figure 1,
n = 5 for each group, * P < 0.05).
The voltage gated calcium current in colonic DRG neurons
The colonic sensory neurons were retrograde traced
with DiI and were isolated for patch clamp recording
(Figure 2A and B). The total IBa current trace of colonic
sensory neurons from control and TNBS treated rats were
elicited by square-wave voltage commands (a 300 ms
voltage step from −80 to 50 mV with 10 mV increments in
3 s intervals) (Figure 2C and D). The peak I-V curves are
shown in Figure 2E. The peak IBa density was significantly
increased in colonic neurons of TNBS treated rats
compared with control (Figure 2F; -127.82 ± 20.82 pA/pF
Vs −91.67 ± 19.02 pA/pF, n = 9, *P < 0.05).
To distinguish different type of calcium currents (L-, N-,
P/Q and R-type), the corresponding selective channel
blockers nimodipine (5 μM, L-type), ω-conotoxin GVIA
(1 μM, N-type), ω-agatoxin IVA(400 nM, P/Q-type) and
Cd2+ (300 μM, R-type) were applied to the recording
chamber. In this protocol, the cells were depolarized
from −60 to 0 mV for 240 ms to elicit the high voltage
activated IBa. The representative current traces and time
course are shown in Figure 3A. The fraction of L-type
IBa (−38.56 ± 3.97 pA/pF Vs −25.75 ± 3.35 pA/pF, n = 9,
* P < 0.05) and R-type IBa (−13.31 ± 1.36 pA/pF Vs −8.60 ±
1.25 pA/pF, n = 9 for each group, *P < 0.05) were signifi-
cantly greater in colonic DRG neurons of TNBS treated
rats than control rats (Figure 3B). There was no significant
difference in the fraction of N- and P/Q-type calcium cur-
rents reduced by ω-conotoxin GVIA and ω-agatoxin IVA.
Table 1 List of the strongly regulated genes in DRGs of TNBS treated rats
Ref. or Acc. number Symbol Gene name TNBS/Con(mean ± SD)
Channels
AY323810 Cacna1c calcium channel, voltage-dependent, L type, alpha 1C subunit 18.45 ± 1.62
NM_019294 Cacna1e calcium channel, voltage-dependent, L type, alpha 1E subunit 14.82 ± 1.51
XM_341818 Ryr1 ryanodine receptor 1, skeletal muscle 13.50 ± 1.23
NM_012825 Aqp4 aquaporin 4 10.26 ± 1.21
NM_019256 P2rx7 purinergic receptor P2X, ligand-gated ion channel, 7 3.75 ± 0.81
XM_233477 Kcnq4 potassium voltage-gated channel, subfamily Q, member 4 3.03 ± 0.57
XM_344426 Kctd9 potassium channel tetramerisation domain containing 9 2.76 ± 0.32
NM_017261 Gria2 glutamate receptor, ionotropic, AMPA2 2.47 ± 0.29
NM_017303 Kcnab1 Potassium voltage-gated channel, shaker-related subfamily, beta member 1 2.25 ± 0.27
NM_031046 Itpr2 inositol 1,4,5-triphosphate receptor 2 2.17 ± 0.25
AI407979 Fxyd5 FXYD domain-containing ion transport regulator 5 0.46 ± 0.04
NM_053870 Kcnj4 potassium inwardly-rectifying channel, subfamily J, member 4 0.44 ± 0.05
AF313481 Trpc3 transient receptor potential cation channel, subfamily C, member 3 0.27 ± 0.04
Receptor
NM_012585 Htr1a 5-hydroxytryptamine (serotonin) receptor 1A 9.87 ± 1.32
NM_012675 Tnf tumor necrosis factor (TNF superfamily, member 2) 8.94 ± 1.21
M64867 Htr2a 5-hydroxytryptamine (serotonin) receptor 2A 5.12 ± 0.98
NM_053429 Fgfr3 fibroblast growth factor receptor 3 4.81 ± 0.84
NM_001002853 P2ry13 purinergic receptor P2Y, G-protein coupled, 13 2.92 ± 0.45
BC087035 Tgfbr1 transforming growth factor, beta receptor 1 2.68 ± 0.46
NM_001013032 Npy1r neuropeptide Y receptor Y1 2.31 ± 0.30
NM_031569 Oprl1 opioid receptor-like 1 2.26 ± 0.23
NM_031088 Ptger2 prostaglandin E receptor 2, subtype EP2 2.26 ± 0.25
NM_053552 Tnfsf4 tumor necrosis factor (ligand) superfamily, member 4 2.15 ± 0.14
NM_012800 P2ry1 purinergic receptor P2Y, G-protein coupled 1 2.10 ± 0.10
XM_217136 Cd3g CD3 antigen, gamma polypeptide 0.47 ± 0.05
NM_019198 Fgf17 fibroblast growth factor 17 0.42 ± 0.06
NM_138880 Ifng interferon gamma 0.36 ± 0.04
NM_053680 Insl3 insulin-like 3 0.02 ± 0.01
Signal transduction-related molecules
AW526572 RragB Ras-related GTP binding B 12.28 ± 1.89
XM_220933 Arf4l ADP-ribosylation factor 4-like 6.06 ± 0.64
XM_343450 Rasa2 RAS p21 protein activator 2 4.44 ± 0.41
NM_133392 Stk17b serine/threonine kinase 17b (apoptosis-inducing) 3.13 ± 0.30
NM_031622 Mapk6 mitogen-activated protein kinase 6 (ERK 3) 3.00 ± 0.34
XM_236242 Rab39 RAB39, member RAS oncogene family 2.73 ± 0.31
NM_134346 Rap1b RAS related protein 1b 2.69 ± 0.36
NM_031130 Nr2f1 nuclear receptor subfamily 2, group F, member 1 2.59 ± 0.29
XM_342223 Prkci protein kinase C, iota 2.46 ± 0.26
NM_022692 Rab5a RAB5A, member RAS oncogene family 2.36 ± 0.26
XM_225020 Rasa3 RAS p21 protein activator 3 2.34 ± 0.24
XM_341399 Mapk8 mitogen-activated protein kinase 8 (JNK 1) 2.33 ± 0.28
NM_053522 Rhoq ras homolog gene family, member Q 2.19 ± 0.18
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Table 1 List of the strongly regulated genes in DRGs of TNBS treated rats (Continued)
M83679 Rab15 RAB15, member RAS onocogene family 2.17 ± 0.16
NM_021763 Arfip1 ADP-ribosylation factor interacting protein 1 2.14 ± 0.14
NM_053306 Pak2 p21 (CDKN1A)-activated kinase 2 2.07 ± 0.10
XM_232732 Map3k6 mitogen-activated protein kinase kinase kinase 6 0.49 ± 0.04
BF403410 Camk2b Calcium/calmodulin-dependent protein kinase II, beta 0.46 ± 0.04
NM_031716 Wisp1 WNT1 inducible signaling pathway protein 1 0.45 ± 0.04
NM_133568 Rasd2 RASD family, member 2 0.38 ± 0.05
XM_215821 Usp8 ubiquitin specific protease 8 0.36 ± 0.04
AA945841 Rab10 RAB10, member RAS oncogene family 0.33 ± 0.05
Data are presented as mean ± SD, n = 4.
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SNX-482
Compared with control rats, the TNBS treated rats
had significantly higher response to colonic distension
(at 1, 2 and 3 ml distention volumn), indicating that
TNBS treated rats were more sensitive to CRD which was
called visceral hypersensitivtiy (Figure 4A, B, # P < 0.05). To
investigate whether elevated L-type and R-type calcium
current in colonic DRG nerons plays a causal role in TNBS
induced inflammatory visceral allodynia, we treated the
TNBS clystered rats with L-type (nimodipine) and R-type
(SNX-482) selective channel blockers by intrathecal
injection. The result showed that the intrathecal in-
jection both nimodipine and SNX-482 significantly
reduced visceromotor response to CRD at 1, 2 and
3 ml distention volumn (Figure 4A, B, * P < 0.05), while
the vehicle treatments had no effect. The visceral
mechanosensitivity of control rats did not change following
intrathecal channel blockers.
Discussion
In this study, we perform a microarray screening for genes
with different expression in rat models of inflammatory
visceral pain and demonstrate that Cav1.2 and Cav2.3
participates in the visceral hyperalgesia induced by
TNBS-colitis. The result revealed that the level of Cav1.2
and Cav2.3 protein in L6-S2 DRG were significantly up-
regulated following colitis and L-type and R-type calcium
currents significantly increased in colonic specific DRG
neurons, while visceral sensitivity to mechanical stimuli alsoTable 2 Real time TR-PCR analysis for quantification of
Cav1.2 and Cav2.3 expression levels
Gene bank accession no. Control (ΔCt1) TNBS (ΔCt2)
AY323810 12.81 ± 0.87 9.23 ± 0.64 *
(Cav1.2)
NM_019294 15.28 ± 1.12 12.11 ± 0.76 *
(Cav2.3)
Data are presented as mean ± SD, n = 4, * P < 0.05.increased significantly. Intrathecal administration of the
specifically inhibits nimodipine and SNX482 reduced the
colonic hyperalgesia to balloon distention.
Genes regulated in the L6-S2 DRG with TNBS treated
may contribute to a variety of biologic processes such as
inflammatory visceral pain signaling. In this study, we
found that a large number of ion channels strongly
regulated in DRG after TNBS treated such as VGCC
(Cav1.2, Cav2.3), inositol 1,4,5-trisphosphate receptor 2,
ryanodine receptors 1(RyR1), P2X7, P2Y and so on.
Some studies have reported about the role of these
channel in pain sensation such as RyR1 [7] P2X7 [8-13]
and P2Y1 [14]. But these channels haven’t been studied
in visceral sensation. In addition, P2X7 and P2Y1 recep-
tors involved in the neuronal soma-satellite cell inter-
action [13,15]. Maybe the up-regulation of P2X7 and
P2Y1 can improve the neuron–glia communication. We
also found that a large number of neurotransmitter and
receptor strongly regulated in DRG after TNBS treated
such as tumor necrosis factor (TNF, member 2 and 4),
PGER(EP2), 5-HTR 1A, 5-HTR 2A and FGFR3, which
upregulated in DRG of TNBS treated rat. Recently, sev-
eral studies provided evidence that TNF-α may act on
primary afferent neurons and induces hypersensitivity
[12,16,17]. Whether the up-regulation of EP2 in L6-S2
DRGs of TNBS treated rats, mediating the visceral
hypersensitivity, needed further study. The previous
studies have suggested that 5-HT1A, 5-HT2A, 5-HT2C,
5-HT3 and 5-HT4 receptor subtypes in the DRG play
important roles in facilitating peripheral nociceptive
transmission [18-20]. Besides the ion channels and re-
ceptors, signal transduction molecules were also signifi-
cantly changed. These changes could be associated with
the rearrangement of pain sensory pathways that take
place during the development of visceral inflammatory
pain. All these changed genes maybe establish a positive
feedback loop between neuron-neuron and neuron-
satellite cell, thus contributing to exaggerated responses
under pathological conditions which still need further
experimental research proof.
Figure 1 Cav1.2 and Cav2.3 subunit protein level in L6-S2 DRGs in control and TNBS treated rats. (A) Representative Western blot for Cav1.2 in
extracts from L6-S2 DRGs showing a prominent band at ~197 kDa. (B) Representative Western blot for Cav2.3 in extracts from L6-S2 DRGs showing a
prominent band at ~251 kDa. (C) The densitiometric analysis of western blot. Bar charts show that the expression of Cav1.2 and Cav2.3 significantly
increased in TNBS treated rats (n = 5 for each group, * P < 0.05). Data are presented as mean ± SD of 5 different rats from each group.
Figure 2 Voltage gated Ca2+ current of DiI+ DRG neurons from control and TNBS treated rats. A, The photomicrograph of dissociated L6-S2 DRG
neurons. B, DiI-labeled neuron (arrow) is visualized under epifluorescence illumination. C, Representative total IBa currents traces of DiI+ neurons from
control rats. D, Representative total IBa currents traces of DiI+ neurons from TNBS treated rats. E, Current–voltage relationships (I-V curves). Current–voltage
plot of average data shows an increase of peak current in colonic neurons from TNBS treated rats (open circle) compared with control rats (square). F, Bar
graph shows peak current density of IBa currents. The average peak IBa currents of colonic neurons from TNBS treated rats were significantly increased
compared with control rats (−127.82 ± 20.82 pA/pF Vs −91.67 ± 19.02 pA/pF, n = 9 for both; * P < 0.05). Scale bar for A and B =30 μm.
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Figure 3 Comparison of the L-type and R-type high voltage activated Ca2+ currents (HAV) of DiI+ DRG neurons from control and TNBS treated
rats. (A) Examples of the current traces (upper row) and the time course (lower row) with differrent calcium channel blockers on IBa in colonic specific
DRG neurons of control group (left, capacitance = 23.3 PF) and TNBS group (Right, capacitance = 24.8 PF). Currents were elicited by depolarizing neurons
from −60 to 0 mV for 240 ms. (B) Changes of the current density of L-type and R-type current. The Bar graphs show that the density of L-type current
(−38.56 ± 3.97 pA/pF Vs −25.75 ± 3.35 pA/pF, n = 9 for each group, * P < 0.05) and R-type current (−13.31 ± 1.36 pA/pF Vs −8.60 ± 1.25 pA/pF, n = 9 for
each group, *P < 0.05) significantly increased in colonic specific DRG neurons of TNBS group compared with control group.
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the function of L- and R- type VGCC were upregulated
in colonic DRG neurons of TNBS treated rats compare
with control group. Kania has reported L-type VGCC
blockers (nifedipine, diltiazem verapamil) can be useful
in controlling acute visceral pain in the model of visceral
pain or hypersensitivity of sheeps, which suggests that
L-type VGCC play a crucial role in the modulation of
acute visceral hyperalgesia [21-23]. They only use the
pharmacology method in the behavioral test lacking the
studies of molecular mechanism. In addition to visceral
pain, neuronal L-type VGCCs Cav1.2 and Cav1.3 have
reported to be up- or down regulated in the model of
neuropathic pain in rats [24,25]. R-type Ca2+ channels
located at primary synapses [26] and can contribute to
neurotransmitter release [27]. R-type VGCCs are associated
with nociceptive processing in various pain conditions.Mathews reported that spinal SNX-482, an R-type VGCC
blocker, inhibited noxious C-fiber and Aδ-fiber-mediated
dorsal horn neuronal responses in conditions of neur-
opathy, not in sham operated rats and that non-noxious
Aδ-mediated responses did not affect by SNX-482 [28]. In
another study, mice lacking the α1E Ca2+ channel subunit
exhibited normal pain behavior against acute mechanical,
thermal, and chemical stimuli; however, they showed
reduced responses to somatic inflammatory pain [29].
So far, there has been no definitive study that shows
that the role of R-type VGCC in visceral sensation. Our
results revealed that upregulated Cav1.2 (L-type) and
Cav2.3 (R-type) maybe involved in the inflammatory
visceral hypersensitivity induced by TNBS treated.
The VGCCs manage and adjust neurotransmitter release
and Ca2+-dependent depolarization that contribute to the
characteristic firing patterns of most neurons, including
Figure 4 Summary data of the mean AWR to CRD following TNBS in rats treated with vehicle or nimodipine and vehicle or SNX-482. A. The
AWR score significantly increased at distension volume at 1.0 2.0 and 3.0 ml 4 days following intracolonic TNBS compared with control rats (n = 9,
# p < 0.05) indicating the development of visceral hyperalgesia. There was a significantly decrease in the AWR in the TNBS treated rats that received
nimodipine (n = 9, * P < 0.05) and there was no difference in the AWR in the rats that received vehicle. B. The AWR score significantly increased at
distension volume at 1.0 2.0 and 3.0 ml 4 days following intracolonic TNBS compared with control rats (n = 9, # p < 0.05). There was a significantly decrease
in the AWR in the TNBS treated rats that received SNX-482 (n = 9, * P < 0.05) and there was no difference in the AWR in the rats that received vehicle.
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was not consensus. Because a change in [Ca2+]i can affect
neuronal properties via changes in ion channel activity
[30,31], enzymatic activity [32] and/or gene expression [33],
the physiological impact of the inflammation induced
changes in evoked increases in [Ca2+]i will depend on
where in the neuron they are manifest. On the other hand,
an increase in [Ca2+]i close to functional Ca
2+ dependent
K+ channels should increase K+ channel activity resulting
in a decrease in afferent excitability and the transmission of
nociceptive information, while a change in the dynamics of
Ca2+ signaling in the cell body may result in changes in
gene expression that are either pro- or anti-nociceptive
[34]. Thus, the colon inflammation-induced changes in the
regulation of [Ca2+]i may contribute to the visceral inflam-
matory hyperalgesia or serve as a feedback inhibitory mech-
anism functioning as a “break” to a host of pro-nociceptive
inflammatory processes. We further detected the visceral
pain after intrathecal injection of specific calcium channel
inhibitors. Nimodipine specifically inhibits Cav1.2 α1C and
to a lesser extent T-type VGCC in central and peripheral
neurons. But the concentration for T-type Ca2+ channel in-
hibition is two orders of magnitude higher than for L-type
Ca2+ channel [35]. The SNX-482 is specific inhibitor for
Cav2.3. Cav1 (L-type) can be partially inhibited by saturat-
ing concentrations of SNX-482 [36]. SNX-482 is a large
peptide and the concentration of SNX-482 applied was
5 μg/Kg. The concentration in the tissue were limited and
this concentration can’t inhibit the Cav1 [28]. As the
intrathecal injection of nimodipine or SNX-482 signifi-
cantly reduced the visceral inflammatory hyperalgesia
in this study, we supposed that Cav1.2 and Cav2.3 may
contribute to the visceral inflammatory hypersensitivity.However, additional experiments will be needed to study
the direct consequence of the increase of [Ca2+]i on
function of the sensory neurons.
In summary, our data revealed that there are many
genes marked changed in L6-S2 DRGs of visceral
inflammatory model, which encompass a large number
of distinct family members including neuropeptides,
receptors, ion channels, signal transduction molecules and
others. Among these changed genes, the up-regulation of
Cav1.2 and Cav2.3 contributed to visceral inflammatory
hyperalgesia, which maybe the potential therapeutic
targets for visceral pain.
Materials and methods
Experimental colitis
Experiments were performed on male Sprague–Dawley
(SD, 200 g-250 g) rats. All animal procedures used in
this study were approved by Medicine Animal Care and
Use Committee of Shanghai Jiaotong University School and
were in accordance with the guidelines of the International
Association for the Study of Pain. To induce inflammation
in the distal colon, fasted rats were anaesthetized and TNBS
(0.6 ml of 30 mg/ml TNBS in 50%Ethanol) was instilled
into the lumen of the colon through a syringe-attached
polyethylene catheter via the rectum 6 cm proximal to the
anus. Animals that received an equal volume of 50%
EtOH enema served as controls throughout these studies.
All colonic instillations were performed under isoflurane
(2%) anaesthesia.
Agilent DNA microarray analysis
After the 4-day recovery period, four rats from each
group were terminally anesthetized with CO2, and then
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Total RNA of DRG (L6-S2) from each group was extracted
using Trizol (Invitrogen Inc., Carlsbad, CA, USA) and puri-
fied with the RNeasy Mini Kit (Qiagen, Hilden, Germany).
The cDNA used for microarray analysis was prepared
by the SuperAmpTM PCR based amplification method
performed according to Miltenyi Biotec’s undisclosed
protocol. Probe labelling was performed according to
Miltenyi Biotec’s undisclosed protocol. The cDNA was
denatured for 4 min at 70°C and cooled down to room
temperature. Afterwards, 11 μL 10× control target solution,
11 μL 10× blocking agent solution (Agilent), and 55 μl
2× Gene Expression hybridization buffer (Agilent) was
added. The entire volume of the reaction was subsequently
hybridized overnight (17 h, 65°C) on Agilent Whole
Rat Genome Oligo Microarrays (4 × 44 K format) using
Agilent’s recommended hybridization chamber and oven.
The microarrays were washed once with 6× SSPE buffer
containing 0.005% Nlauroylsarcosine for 1 min, followed
by a second wash with 0.06× SSPE containing 0.005%
Nlauroylsarcosine for 1 min, and a final wash step with
acetonitrile for 30 s. The fluorescence signals of the hybrid-
ized Agilent Microarrays were detected using Agilent’s
Microarray Scanner System (Agilent).
Data were imported into Genedata Expressionist
Analyst (Genedata AG, Basel, Switzerland), and the
Cyanine 3 fluorescence intensities normalized using
lowest weighted linear regression (LOWESS). Normalized
data in tab delineated text format were uploaded into NIA
array analysis (http://lgsun.grc.nia.nih.gov/ANOVA); this
allowed a pairwise comparison of gene signal intensity
(expression) with fold difference of two or greater, as
determined by single factor analysis of variance with
multiple hypothesis correction by the false discovery
rate. The fold change was calculated for each sample to
represent a ratio of expression between TNBS treated
and control samples.
Validation of gene transcription by real-time PCR
RT- PCR was carried out on the same set of samples
that were analyzed by the microarray approach. Three
μg total RNA of each tested sample was used for reverse







Quantitative PCR was performed in 25 μL with the ABI
Power SYBR Green PCR Master Mix (ABI, USA) on the
7300 Sequence Detection System (ABI, USA). Thermalcycling was initiated with incubation at 50°C for 2 min
and 95°C for 10 min. After this initial step, 40 cycles of
PCR were performed. Each PCR cycle consisted of heating
at 95°C for 15 s for melting and 60°C for 1 min for
annealing and extension. All RT-PCRs were performed in
triplicate, and the results were normalized with the Ct
values of β-actin.
Western blot
The western blot for protein expression of DRGs was done
as previous reported [37]. Animals (5 rats of each group)
were terminally anesthetized with CO2, the L6-S2
DRGs-containing colon afferent rapidly removed, and
stored at −80°C. Protein extracts from pooled DRG (L6-S2)
were prepared in SDS buffer: 50 mM Tris–HCl, 133 mM
NaCl, 2%SDS, 1 mM DTT, 1 mM PMSF, 1:100 dilution of
protease inhibitor cocktail (sigma), pH = 8. Twenty-five
micrograms (25 μg) of protein were loaded onto 9%
SDS-PAGE, and electrophoretically transferred to PVDF
membrane (Bio-Rad, Hercules, CA) at 100 V for 2 h. The
membranes were blotted with antibodies against Cav1.2
and Cav2.3 (sigma, dilution 1:200), followed by incubation
with horseradish peroxidase (HRP)-conjugated secondary
antibody (Dako Cytomation, Denmark). Bands were visual-
ized using ECL (Amersham) kit and appropriate exposure
to Kodak X-ray film. Films were scanned and band
intensities measured using Gel-pro Analyzer 4.0 software
(Media Cybernetics). Cav1.2 and Cav2.3 protein expression
were normalized to β-actin.
Isolation and identification of distal colon projecting DRG
neurons
Colon specific DRG neurons were labelled by injec-
tion of 1,10-dioleyl-3,3,30,3-tetramethylindocarbocyanine
methanesulfonate (DiI, Invitrogen) into the colon wall,
which has been described previously report [37]. After
1 wk of DiI labeling, TNBS colitis was induced as previous.
4 days later, colonic DRG neurons from both groups were
used for recording voltage-gated calcium current. Isolation
of DRG neurons from these adult SD rats has been
described previously report [37].
Electrophysiological recordings
The whole cell patch clamp recording of DiI+ has been
described previously report [37]. Patch electrodes with a
resistance of 2–4 MΩ were pulled from borosilicate
glass capillaries (ID 0.86 mm, OD 1.5 mm, Length
10 cm, Sutter Instruments) using a micropipette puller
(P-97 Sutter Instruments, Novato, CA). Neurons were
patched in the whole cell configuration and recorded using
an EPC-10 amplifier (HEKA Instruments, Lambrecht,
Germany). Seals (1–10 GΩ) between the electrode and the
cell were established. After whole cell configuration
was established, the cell membrane capacitance and series
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were only made when access resistance fell to <15 MΩ.
Up to 80% of the series resistance was compensated elec-
tronically. Leak currents were subtracted using the on-line
P/4 protocol. Barium currents (IBa) flowing through
calcium channels were recorded using extracellular solution
consisting of (in mM): 140 TEA-Cl, 2 MgCl2, 3 BaCl2, 10
glucose, 10 HEPES (pH 7.4 adjusted with TEA-OH,
osmolarity 320). The pipette solution contained (in mM):
120 CsCl, 1 MgCl2, 10 HEPES, 10 EGTA, 4 Mg-ATP and
0.3 Na-GTP (pH 7.2 adjusted with CsOH, osmolarity
300 mOsm). To minimize the “run-down” associated with
the whole-cell recording, GTP and ATP were included in
the pipette solution. The total IBa was elicited by a 300 ms
voltage step from −80 to 50 mV with 10 mV increments in
3 s intervals (holding potential, −100 mV). The high voltage
actived IBa was elicited by a 240 ms voltage step from −60
to 0 mV (holding potential, −60 mV). ω-conotoxin
GVIA and ω-agatoxin IVA were dissolved in distilled
water at 1000 times the final concentration and kept
frozen in aliquots. Nimodipine was prepared as a stock
solution dissolved in DMSO. To distinguish the L-, N-, and
P/Q-type calcium currents in DiI+ DRG neurons, the
corresponding selective channel blockers nimodipine
(5 μM, L-type), ω-conotoxin GVIA (1 μM, N-type), ω-
agatoxin IVA (400 nM, P/Q-type) and Cd2+ (300 μM,
R-type) were applied to the same recording neurons.
The stock solutions were diluted in extracellular solution
just before use and held in a series of independent
syringes connected to corresponding fused silica columns
(ID 200 μm). Each drug solution was delivered to the
recording chamber by gravity flow, and rapid solution
exchange was achieved by controlling the corresponding
valve switch (World Precision Instruments). All drugs and
chemicals were all purchased from Sigma.
Intrathecal catheters
Chronic intrathecal catheters were implanted three days
before TNBS induced colitis. Following anaesthetized with
1% pentobarbital sodium 100 mg/kg intraperitoneally.
The L3 and L4 vertebrae were exposed. A 32-gauge poly-
imide catheter was then threaded into the subarachnoid
space and passed in a caudal direction for approximately
3 cm. The external end of the catheter was connected to a
length of PE-10 polyethylene tubing which was tunnelled
and exteriorised over the forehead. Animals were
then caged individually. Any animal developing motor
impairment following catheter placement was excluded
from the study. All the drugs were given intrathecally
in a total volume of 10 μL. The channel blockers were
injected twice daily for 4 d, starting from the TNBS
treated day. The nimodipine was dissolved in DMSO and
SNX-482 was dissolved in sterile saline. Nimodipine
(20 μg/kg) and SNX-482(5 μg/kg) were administered as abolus via the intrathecal catheter in volumes of 10 μl. The
catheter was flushed afterwards with 10 μl saline. The
same amount of vehicle (DMSO or 0.9%NaCl) was
injected into some TNBS treated rats as vehicle control.
Behavioral testing was performed after the last injection
on the fourth day of TNBS treatment as described below.
Behavioral testing for nocifensive response
We used a grading system based on the abdominal with-
drawal reflex (AWR) in response to colorectal distention
(CRD) to evacuate the visceral sensitivity. Briefly, under
sedation with aether, a flexible latex balloon (5 cm) attached
to the perforated end of an arterial embolectomy probe
(LeMaitre Embolectomy Catheter 6F; LeMaitre Vascular)
was inserted 6–8 cm into the descending colon and rectum
via the anus and held in place by taping the tubing to the
tail. CRD was performed by rapidly inflating the balloon to
a constant volumn. The balloon was inflated to 1, 2, 3 and
4 ml, for 20 s followed by 2 min rest. Behavioral response
to CRD was measured by visual observation of the AWR
by an observer blind to the experimental conditions, and
AWR was scored as: 1 (normal behavior), 2 (contraction of
abdominal muscles), 3 (lifting of abdominal wall), or 4
(body arching and lifting of pelvic structures).
Statistical analysis
Data were statistically analyzed by analysis of variance
(ANOVA) and sequential differences between means were
tested by Tukey contrast analysis at P < 0.05.
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